Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Survival with Cemiplimab in Recurrent Cervical Cancer
Krishnansu S. Tewari, Bradley J. Monk, Ignace Vergote, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 6, pp. 544-555
Open Access | Times Cited: 303

Showing 1-25 of 303 citing articles:

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 228
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
Linda Mileshkin, Kathleen N. Moore, Elizabeth H Barnes, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 5, pp. 468-482
Open Access | Times Cited: 100
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
Bradley J. Monk, Takafumi Toita, Xiaohua Wu, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 12, pp. 1334-1348
Closed Access | Times Cited: 100
European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023
Maaike H.M. Oonk, François Planchamp, Peter Baldwin, et al.
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 7, pp. 1023-1043
Open Access | Times Cited: 92
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
The Lancet (2023) Vol. 403, Iss. 10421, pp. 31-43
Open Access | Times Cited: 89
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials
Bradley J. Monk, Takayuki Enomoto, W. Martin Kast, et al.
Cancer Treatment Reviews (2022) Vol. 106, pp. 102385-102385
Open Access | Times Cited: 85
Recurrent or primary metastatic cervical cancer: current and future treatments
Christine Gennigens, Guy Jérusalem, L. Lapaille, et al.
ESMO Open (2022) Vol. 7, Iss. 5, pp. 100579-100579
Open Access | Times Cited: 77
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 6, pp. 755-768
Open Access | Times Cited: 46
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
Bradley J. Monk, Krishnansu S. Tewari, Coraline Dubot, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 4, pp. 392-402
Open Access | Times Cited: 42
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 1, pp. 44-55
Closed Access | Times Cited: 39
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
The Lancet (2024) Vol. 404, Iss. 10460, pp. 1321-1332
Closed Access | Times Cited: 29
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
Ana Oaknin, Kathleen N. Moore, Tim Meyer, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 5, pp. 588-602
Closed Access | Times Cited: 26
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1501-1508
Open Access | Times Cited: 17
Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)
Szu‐Ting Yang, Peng‐Hui Wang, Hung‐Hsien Liu, et al.
Taiwanese Journal of Obstetrics and Gynecology (2024) Vol. 63, Iss. 5, pp. 637-650
Open Access | Times Cited: 15
Cervical Cancer
Krishnansu S. Tewari
New England Journal of Medicine (2025) Vol. 392, Iss. 1, pp. 56-71
Closed Access | Times Cited: 2
Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines
Qian Zheng, Misi He, Zejia Mao, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 92-92
Open Access | Times Cited: 1
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 30, pp. 4768-4778
Open Access | Times Cited: 37
Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
Zherui Liu, Yun Zhu, Huan Xie, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 33
The Immune Regulatory Role of Adenosine in the Tumor Microenvironment
Jianlei Xing, Jinhua Zhang, Jinyan Wang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14928-14928
Open Access | Times Cited: 30
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors
Philipp Knopf, Dimitri Stowbur, Sabrina H. L. Hoffmann, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Challenges in the Diagnosis and Individualized Treatment of Cervical Cancer
Melanie Schubert, Dirk Bauerschlag, Mustafa Zelal Muallem, et al.
Medicina (2023) Vol. 59, Iss. 5, pp. 925-925
Open Access | Times Cited: 25
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Krishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk, et al.
JAMA Oncology (2023) Vol. 10, Iss. 2, pp. 185-185
Closed Access | Times Cited: 24
Advances in immunotherapy for cervical cancer
Juan Francisco Grau-Béjar, Carmen García-Durán, David García-Illescas, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 22
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong‐Man Kim, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 8, pp. 1140-1148
Closed Access | Times Cited: 14
Cervical cancer: a new era
Giuseppe Caruso, Matthew K. Wagar, Heng‐Cheng Hsu, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 12, pp. 1946-1970
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top